TREA

97855612 - HEPNET

Follow

Information

  • Trademark
  • 97855612
  • Serial Number
    97855612
  • Registration Number
    7575493
  • Filing Date
    March 24, 2023
    3 years ago
  • Registration Date
    November 26, 2024
    a year ago
  • Transaction Date
    November 26, 2024
    a year ago
  • Status Date
    November 26, 2024
    a year ago
  • Published for Opposition Date
    March 12, 2024
    2 years ago
  • Location Date
    November 25, 2024
    a year ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    WOOD, CAROLINE
  • Attorney Docket Number
    210309.00127
    Attorney Name
    Anna King
  • Owners
Information
Mark Drawing Code
4
Mark Identification
HEPNET
Case File Statements
  • GS0401: Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
  • GS0091: Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
  • GS0051: Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
  • GS0421: Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Case File Event Statements
  • 3/28/2023 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 4/16/2023 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/25/2023 - 3 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/27/2023 - 3 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/27/2023 - 3 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/27/2023 - 3 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 5/18/2023 - 3 years ago
    7 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/18/2023 - 3 years ago
    8 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 5/18/2023 - 3 years ago
    9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 7/31/2023 - 3 years ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 12/26/2023 - 2 years ago
    11 - ASSIGNED TO LIE Type: ALIE
  • 12/26/2023 - 2 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/26/2023 - 2 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/30/2024 - 2 years ago
    14 - PRIORITY ACTION WRITTEN Type: CPRA
  • 1/30/2024 - 2 years ago
    15 - PRIORITY ACTION E-MAILED Type: GPRA
  • 1/30/2024 - 2 years ago
    16 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN
  • 1/30/2024 - 2 years ago
    17 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/30/2024 - 2 years ago
    18 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/30/2024 - 2 years ago
    19 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 2/21/2024 - 2 years ago
    21 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 2/2/2024 - 2 years ago
    20 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 2/21/2024 - 2 years ago
    22 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 3/12/2024 - 2 years ago
    23 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 5/7/2024 - 2 years ago
    25 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 3/12/2024 - 2 years ago
    24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 11/4/2024 - a year ago
    27 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN
  • 11/4/2024 - a year ago
    26 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR
  • 11/5/2024 - a year ago
    28 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B
  • 11/26/2024 - a year ago
    29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/26/2024 - a year ago
    30 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC